C H Chung1, J W Lee2, R J Slebos3, J D Howard4, J Perez4, H Kang4, E J Fertig4, M Considine4, J Gilbert5, B A Murphy5, S Nallur6, T Paranjape6, R C Jordan7, J Garcia8, B Burtness9, A A Forastiere4, J B Weidhaas10. 1. Department of Oncology; Department of Otolaryngology-Head and Neck Surgery, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore. Electronic address: cchung11@jhmi.edu. 2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston. 3. Department of Cancer Biology. 4. Department of Oncology. 5. Division of Hematology/Oncology, Department of Medicine, Vanderbilt University, Nashville. 6. Department of Therapeutic Radiology. 7. Department of Pathology, University of California, San Francisco. 8. Mayo Clinic, Rochester, USA. 9. Section of Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven. 10. Department of Therapeutic Radiology; Department of Radiation Oncology, University of California, Los Angeles.
Abstract
BACKGROUND: A germline mutation in the 3'-untranslated region of KRAS (rs61764370, KRAS-variant: TG/GG) has previously been associated with altered patient outcome and drug resistance/sensitivity in various cancers. We examined the prognostic and predictive significance of this variant in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS: We conducted a retrospective study of 103 HNSCCs collected from three completed clinical trials. KRAS-variant genotyping was conducted for these samples and 8 HNSCC cell lines. p16 expression was determined in a subset of 26 oropharynx tumors by immunohistochemistry. Microarray analysis was also utilized to elucidate differentially expressed genes between KRAS-variant and non-variant tumors. Drug sensitivity in cell lines was evaluated to confirm clinical findings. RESULTS: KRAS-variant status was determined in 95/103 (92%) of the HNSCC tumor samples and the allelic frequency of TG/GG was 32% (30/95). Three of the HNSCC cell lines (3/8) studied had the KRAS-variant. No association between KRAS-variant status and p16 expression was observed in the oropharynx subset (Fisher's exact test, P = 1.0). With respect to patient outcome, patients with the KRAS-variant had poor progression-free survival when treated with cisplatin (log-rank P = 0.002). Conversely, KRAS-variant patients appeared to experience some improvement in disease control when cetuximab was added to their platinum-based regimen (log-rank P = 0.04). CONCLUSIONS: The TG/GG rs61764370 KRAS-variant is a potential predictive biomarker for poor platinum response in R/M HNSCC patients. CLINICAL TRIAL REGISTRATION NUMBERS: NCT00503997, NCT00425750, NCT00003809.
BACKGROUND: A germline mutation in the 3'-untranslated region of KRAS (rs61764370, KRAS-variant: TG/GG) has previously been associated with altered patient outcome and drug resistance/sensitivity in various cancers. We examined the prognostic and predictive significance of this variant in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS: We conducted a retrospective study of 103 HNSCCs collected from three completed clinical trials. KRAS-variant genotyping was conducted for these samples and 8 HNSCC cell lines. p16 expression was determined in a subset of 26 oropharynx tumors by immunohistochemistry. Microarray analysis was also utilized to elucidate differentially expressed genes between KRAS-variant and non-variant tumors. Drug sensitivity in cell lines was evaluated to confirm clinical findings. RESULTS: KRAS-variant status was determined in 95/103 (92%) of the HNSCC tumor samples and the allelic frequency of TG/GG was 32% (30/95). Three of the HNSCC cell lines (3/8) studied had the KRAS-variant. No association between KRAS-variant status and p16 expression was observed in the oropharynx subset (Fisher's exact test, P = 1.0). With respect to patient outcome, patients with the KRAS-variant had poor progression-free survival when treated with cisplatin (log-rank P = 0.002). Conversely, KRAS-variant patients appeared to experience some improvement in disease control when cetuximab was added to their platinum-based regimen (log-rank P = 0.04). CONCLUSIONS: The TG/GG rs61764370 KRAS-variant is a potential predictive biomarker for poor platinum response in R/M HNSCC patients. CLINICAL TRIAL REGISTRATION NUMBERS: NCT00503997, NCT00425750, NCT00003809.
Authors: Hiromitsu Hatakeyama; Haixia Cheng; Pamela Wirth; Ashley Counsell; Samuel R Marcrom; Carey Burton Wood; Paula R Pohlmann; Jill Gilbert; Barbara Murphy; Wendell G Yarbrough; Deric L Wheeler; Paul M Harari; Yan Guo; Yu Shyr; Robbert J Slebos; Christine H Chung Journal: PLoS One Date: 2010-09-13 Impact factor: 3.240
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Brock C Christensen; Benjamin J Moyer; Michele Avissar; Lauren G Ouellet; Silvia L Plaza; Michael D McClean; Carmen J Marsit; Karl T Kelsey Journal: Carcinogenesis Date: 2009-04-20 Impact factor: 4.944
Authors: C H Chung; J Aulino; N J Muldowney; H Hatakeyama; J Baumann; B Burkey; J Netterville; R Sinard; W G Yarbrough; A J Cmelak; R J Slebos; Y Shyr; J Parker; J Gilbert; B A Murphy Journal: Ann Oncol Date: 2009-10-22 Impact factor: 32.976
Authors: Joanne B Weidhaas; Jonathan Harris; Dörthe Schaue; Allen M Chen; Robert Chin; Rita Axelrod; Adel K El-Naggar; Anurag K Singh; Thomas J Galloway; David Raben; Dian Wang; Chance Matthiesen; Vilija N Avizonis; Rafael R Manon; Omar Yumen; Phuc Felix Nguyen-Tan; Andy Trotti; Heath Skinner; Qiang Zhang; Robert L Ferris; David Sidransky; Christine H Chung Journal: JAMA Oncol Date: 2017-04-01 Impact factor: 31.777
Authors: Terri P McVeigh; Song-Yi Jung; Michael J Kerin; David W Salzman; Sunitha Nallur; Antonio A Nemec; Michelle Dookwah; Jackie Sadofsky; Trupti Paranjape; Olivia Kelly; Elcie Chan; Nicola Miller; Karl J Sweeney; Daniel Zelterman; Joann Sweasy; Robert Pilarski; Donatello Telesca; Frank J Slack; Joanne B Weidhaas Journal: Cell Cycle Date: 2015-05-11 Impact factor: 4.534
Authors: Elana J Fertig; Hiroyuki Ozawa; Manjusha Thakar; Jason D Howard; Luciane T Kagohara; Gabriel Krigsfeld; Ruchira S Ranaweera; Robert M Hughes; Jimena Perez; Siân Jones; Alexander V Favorov; Jacob Carey; Genevieve Stein-O'Brien; Daria A Gaykalova; Michael F Ochs; Christine H Chung Journal: Oncotarget Date: 2016-11-08